Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study
Abstract Background Heart failure with preserved ejection fraction (HFpEF) is frequently complicated by pulmonary hypertension (PH). A pulmonary vascular contribution could be considered as a substantial therapeutic target in HFpEF and PH and combined pre- and postcapillary PH (Cpc-PH). Methods We e...
Main Authors: | Evgeny Belyavskiy, Artem Ovchinnikov, Alexandra Potekhina, Fail Ageev, Frank Edelmann |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-09-01
|
Series: | BMC Cardiovascular Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12872-020-01671-2 |
Similar Items
-
Heart failure with preserved ejection fraction (HFpEF): Implications for the anesthesiologists
by: Ajmer Singh, et al.
Published: (2018-01-01) -
Effects of empagliflozin on exercise tolerance and left ventricular diastolic function in patients with heart failure with preserved ejection fraction and type 2 diabetes: a prospective single-center study
by: A. G. Ovchinnikov, et al.
Published: (2021-02-01) -
Relationship between plasma aldosterone and left ventricular structure and function in patients with heart failure with preserved ejection fraction
by: A. N. Shevelok
Published: (2021-03-01) -
Targeting heart failure with preserved ejection fraction: current status and future prospects
by: Kanwar M, et al.
Published: (2016-04-01) -
Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
by: Domenico D’Amario, et al.
Published: (2019-11-01)